Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone versus glimepiride added to metformin for beta-cell function in type 2 diabetes
NL-OMON27919Suspended
- Sponsor
- Academic Medical Center
- Start
- Sep 2004
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Metformin + glimepiride with Metformin + rosiglitazone (2 arms). Primary endpoint: Peak insulin concentrations during the hyperglycaemic clamp protocol. Started Sep 2004; status: suspended.
02
Drugs
rosiglitazoneglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON27919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27919.